Results 91 to 100 of about 79,407 (254)

Development of Mucoadhesive Gel Microbicide to Target Mucosal HIV Reservoirs [PDF]

, 2014
The wide use of microbicide is mainly depends on its effectiveness, less frequent application, ready availability and most importantly cost. The aim of this work was to develop affordable microbicide mucoadhesive gel formulation of synthetic anti HIV ...
Shegokar, Ranjita, Singh, Kamalinder K
core   +1 more source

HPV42 – a human papillomavirus classified as a low‐risk type with oncogenic potential

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Human papillomavirus (HPV) type 42 is a rare HPV type currently classified as “low‐risk” and belongs to the alpha genus. It has primarily been detected in benign vulvar papillomas and is predominantly associated with benign lesions such as anogenital warts.
Sven Niklas Burmann, Ulrike Wieland, Steffi Silling, Frank Oellig, David Chromy, Julia Hyun, Thilo Gambichler, Alexander Kreuter   +7 more
wiley   +1 more source

Tenofovir induced lichenoid drug eruption

Avicenna Journal of Medicine, 2015
Cutaneous adverse reactions are a common complication of anti-retroviral therapy. Tenofovir is a newer anti-retroviral drug belonging to the nucleotide reverse transcriptase inhibitor group.
Mrinal Gupta, Heena Gupta, Anish Gupta
doaj   +1 more source

A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To assess the safety, tolerability, and treatment effects of rimegepant 75 mg every other calendar day (EOD) for the preventive treatment of migraine in a 52‐week, open‐label extension (OLE) study. Background Rimegepant is an oral small molecule calcitonin gene–related peptide receptor antagonist approved for the acute treatment of ...
David Kudrow, Robert S. Croop, Alexandra Thiry, Richard B. Lipton   +3 more
wiley   +1 more source

Acute renal failure in an AIDS patient on tenofovir: a case report

Journal of Medical Case Reports, 2008
Introduction Tenofovir is a potent nucleotide analogue reverse-transcriptase inhibitor used with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV) infection.
Kapitsinou Pinelopi P, Ansari Naheed
doaj   +1 more source

Late diagnosis of paediatric HIV infection in high‐income countries: Lessons from the HIV Perinatal Virtual Clinic

HIV Medicine, EarlyView.
Abstract Introduction Timely diagnosis of HIV in children remains a challenge in all settings including low‐prevalence, high‐income countries (HIC). We aimed to characterize the prevalence of late diagnosis, and prior missed diagnostic opportunities among new presentations of paediatric HIV in HIC referred to an international Perinatal Virtual Clinic ...
Carolina Curto, M. Tritzali, A. Bamford, A. C. Bailey, E. G. H. Lyall, N. E. Mackie, N. Tickner, C. Foster, on behalf of the PVC   +8 more
wiley   +1 more source

Early Onset of Tenofovir-Induced Renal Failure: Case Report and Review of the Literature

The Scientific World Journal, 2007
Tenofovir is an acyclic nucleotide analogue reverse transcriptase inhibitor that is commonly prescribed as part of a highly active antiretroviral therapy (HAART) regimen in HIV-infected patients.
Shilpa M. Patel, Teresa R. Zembower, Frank Palella, Yashpal S. Kanwar, Shubhada N. Ahya   +4 more
doaj   +1 more source

Effect of tenofovir Administration And Withdrawl On The Kidney Tissues Of Adult Male Albino Rats And The Protective Role Of Vitamin E

SVU-International Journal of Veterinary Sciences, 2019
Tenofovir disoproxil fumarate is one of antiretroviral drugs used to treat chronic hepatitis B and HIV. In recent studies many Tenofovir problems were recorded; acute kidney injury (AKI), chronic kidney diseases (CKD) and Fanconi syndrome. Vitamin E is
Rasha M. Abd El-Fattah, Dorreia M. Zaghloul, Eman A. Abd Elrahim, Salwa M. Ouies   +3 more
doaj   +1 more source

Tenofovir prodrugs potently inhibit Epstein–Barr virus lytic DNA replication by targeting the viral DNA polymerase

Proceedings of the National Academy of Sciences of the United States of America, 2020
Significance Epstein–Barr virus (EBV)-associated diseases represent a major cause of morbidity worldwide, accounting for at least 1.5% of the global cancer burden, and contributing to autoimmunity.
Natalia Drosu, E. Edelman, D. Housman
semanticscholar   +1 more source

Effectiveness and safety of two‐drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV: Data from the COMBINE‐2 study

HIV Medicine, EarlyView.
Abstract Objectives This study assessed real‐world effectiveness and safety of switching to dual therapy regimens consisting of an integrase inhibitor (INSTI), and reverse transcriptase inhibitor (RTI), among suppressed people living with HIV in Europe.
Cristina Mussini, Cassidy Henegar, Lambert Assoumou, Stephane de Wit, Margaret Johnson, Eugenia Quiros‐Roldan, Chris Kenyon, Colin Deschanvres, David Zucman, Frank Post, Roya Movahedi, Laura Comi, Julie Fox, Geoffrey Liegeon, Charlotte Martin, Jonathan Edwards, Giorgio Tiecco, Marc Delforge, Leigh Ragone, Bryn Jones, Jean van Wyk, Michael Aboud, Carl Fletcher, Anton Pozniak, Vani Vannappagari   +24 more
wiley   +1 more source